Microbiota Changes in Acute Myeloid Leukemia Patients Undergoing Intensive Chemotherapy
NCT ID: NCT03728699
Last Updated: 2023-11-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
54 participants
OBSERVATIONAL
2018-01-02
2022-02-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of FMT in Patients With AML Allo HSCT in Recipients
NCT03678493
Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy
NCT04858594
Chronic Myelod Leukemia Registry at Asan Medical Center
NCT01761695
AML-MDS Novel Prognostic Tests Clinical Study
NCT01685619
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sample Collection Blood
Collected from each patient twice weekly.
Stool Sample
Collected from each patient twice weekly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any intensive chemotherapy regimen defined as a planned \~4 week inpatient stay. Chemotherapy may be delivered for any number of days and on any schedule. Patients may be discharged from the hospital sooner than 4 weeks if the treating physician choose so, but the expectation at the initiation of chemotherapy must be \~4 weeks of inpatient stay, as is typical.
* Able to provide written voluntary consent before performance of any study related procedure.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Masonic Cancer Center, University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM2018-23
Identifier Type: OTHER
Identifier Source: secondary_id
2018NTLS107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.